The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLV. Pleural and/or pericardial involvement

XLV.p Pleuroparenchymal fibroelastosis (PPFE)

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLV. Pleural and/or pericardial involvement

XLV.ac Pneumothorax, bilateral

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LV. Imaging

LV.a Imaging: Diffuse haze

LV. Imaging

LV.b Imaging: Ground-glass opacities (GGO) / shadowing

LV. Imaging

LV.m Imaging: Interlobular septal thickening

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.f Hiccup

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.c Pleuritic chest pain

L. Miscellaneous

L.m Chest deformity: platythorax

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LV. Imaging

LV.ar Imaging: Pleural thickening w/wo rounded atelectasis

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.q Viral pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.ar Interstitial Pneumonitis with Autoimmune Features (IPAF)

I. Interstitial/parenchymal lung disease

I.as The association of ILD and myositis

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.bb Rhabdomyolysis (see also under Xj)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

LI. Cardiovascular involvement / toxicity

LI.ad Pericardial fat necrosis

LV. Imaging

LV.x Imaging: Waxing and waning nodules

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.f BAL: Foamy macrophages

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.g Transfusion-related acute lung injury (TRALI) (May cause ARDS)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.o Engraftment syndrome

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.ai Bronchial stenosis/stricture

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.aa Pseudomembranous tracheitis/tracheobronchitis

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.r Path: Alveolar hemorrhage (see also IIIa)

LVIII. Pathology

LVIII.aq Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.bf Path: Pulmonary cytolytic thrombi

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

LIX. Infections & related conditions

LIX.m Fungal airway infection

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.g BAL: Atypical epithelial cells (at times poetically named

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.br Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

LVIII. Pathology

LVIII.cl Path: Post-transplant lymphoproliferative disease (PTLD)

LIX. Infections & related conditions

LIX.l Scedosporium pulmonary infection

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)